Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.
The study, conducted by the National Human Genome Research Institute (NHGRI) from January 1, 2000, to January 1, 2009, involved 4691 cancer patients who were being treated with chemotherapy in a single outpatient ward. The researchers calculated social influence through the total weighted co-presence among patients, meaning the total time a patient spent with other patients being treated with chemotherapy.
“We had information on when patients checked in and out of the chemotherapy ward, a small intimate space where people could see and interact for a long period of time,” said Jeff Lienert, the lead author in NHGRI’s Social Behavioral Research Branch and National Institutes of Health Oxford-Cambridge Scholars Program fellow. “We used ‘time spent getting chemotherapy in a room with others’ as a proxy for social connection.”
The primary outcome was a patient’s 5-year survival rate which is often regarded as the standard in cancer research. This was determined by the percentage of people who live at least 5 years following the completion of chemotherapy treatment.
The study found that when a patient interacted with someone who died fewer than 5 years post-chemotherapy, they had a 72% chance of also dying within the 5-year period after treatment. However, when patients interacted with someone who survived at least 5 years, their chance of dying within 5 years was at 68%. Furthermore, the researchers predicted that isolated patients had a 69.5% chance of death in the 5 years.
“A 2% difference in survival—between being isolated during treatment and being with other patients—might not sound like a lot, but it’s pretty substantial,” Lienert stated. “If you saw 5000 patients in 9 years, that 2% improvement would affect 100 people.”
The researchers suggest that oncologists consider the social influence by attempting to maximize co-presence among patients through scheduling. Also, patients should be encouraged to find social support in the chemotherapy ward in order to reduce stress.
“Positive social support during the exact moments of greatest stress is crucial. If you have a friend with cancer, keeping him or her company during chemotherapy probably will help reduce their stress,” concluded Lienert. “The impact is likely to be as effective, and possibly more effective, than cancer patients interacting with other cancer patients.”
Social Interaction Among Patients During Chemotherapy Affects Treatment Response
Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.
Social interaction during chemotherapy treatments can positively influence a cancer patient’s health through improving patient outcomes and patient survival rates.
The study, conducted by the National Human Genome Research Institute (NHGRI) from January 1, 2000, to January 1, 2009, involved 4691 cancer patients who were being treated with chemotherapy in a single outpatient ward. The researchers calculated social influence through the total weighted co-presence among patients, meaning the total time a patient spent with other patients being treated with chemotherapy.
“We had information on when patients checked in and out of the chemotherapy ward, a small intimate space where people could see and interact for a long period of time,” said Jeff Lienert, the lead author in NHGRI’s Social Behavioral Research Branch and National Institutes of Health Oxford-Cambridge Scholars Program fellow. “We used ‘time spent getting chemotherapy in a room with others’ as a proxy for social connection.”
The primary outcome was a patient’s 5-year survival rate which is often regarded as the standard in cancer research. This was determined by the percentage of people who live at least 5 years following the completion of chemotherapy treatment.
The study found that when a patient interacted with someone who died fewer than 5 years post-chemotherapy, they had a 72% chance of also dying within the 5-year period after treatment. However, when patients interacted with someone who survived at least 5 years, their chance of dying within 5 years was at 68%. Furthermore, the researchers predicted that isolated patients had a 69.5% chance of death in the 5 years.
“A 2% difference in survival—between being isolated during treatment and being with other patients—might not sound like a lot, but it’s pretty substantial,” Lienert stated. “If you saw 5000 patients in 9 years, that 2% improvement would affect 100 people.”
The researchers suggest that oncologists consider the social influence by attempting to maximize co-presence among patients through scheduling. Also, patients should be encouraged to find social support in the chemotherapy ward in order to reduce stress.
“Positive social support during the exact moments of greatest stress is crucial. If you have a friend with cancer, keeping him or her company during chemotherapy probably will help reduce their stress,” concluded Lienert. “The impact is likely to be as effective, and possibly more effective, than cancer patients interacting with other cancer patients.”
Oncologists Find Ethical Challenges With Artificial Intelligence in Cancer Care
March 28th 2024Explainability, consent, and responsibility are noted as challenges that may hinder implementation of artificial intelligence (AI) in cancer care, according to a new study.
Read More
Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
December 21st 2023Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
Listen
What We’re Reading: Abortion Pill Access Arguments; Clinical Research Site Inspections; AstraZeneca 340B Lawsuit
March 27th 2024The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Venetoclax Resistance in Patients With MDS Explained in New Study
March 26th 2024The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.
Read More
Dupilumab Reduces Asthma Symptoms Regardless of Exacerbation History, Study Finds
March 25th 2024Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.
Read More
Oncologists Find Ethical Challenges With Artificial Intelligence in Cancer Care
March 28th 2024Explainability, consent, and responsibility are noted as challenges that may hinder implementation of artificial intelligence (AI) in cancer care, according to a new study.
Read More
Updates on Adagrasib in CRC and the Importance of Genomic Testing With Dr Jun Gong
December 21st 2023Jun Gong, MD, of Cedars-Sinai Medical Center, discusses the latest data on adagrasib in colorectal cancer, the importance of conducting genomic testing, and more.
Listen
What We’re Reading: Abortion Pill Access Arguments; Clinical Research Site Inspections; AstraZeneca 340B Lawsuit
March 27th 2024The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Venetoclax Resistance in Patients With MDS Explained in New Study
March 26th 2024The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.
Read More
Dupilumab Reduces Asthma Symptoms Regardless of Exacerbation History, Study Finds
March 25th 2024Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.
Read More